Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Central Resistance to Thyroid Hormone in Thyroid Cancer
NCT04868045Phase 1Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of thyrotropin-releasing hormone in thyroid cancer (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Change in peak TSH levels at Day 5. Planned start Apr 2021; status: withdrawn.
02
Drugs
thyrotropin-releasing hormone
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT04868045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04868045.